Send the following on WhatsApp
Continue to Chat羅氏(Roche)旗下血癌藥 Lunsumio 獲捷報,成為首個美 FDA 核准的雙標靶抗體(CD20xCD3)藥物! https://geneonline.news/roche-lunsumio-fda-approved/?variant=zh-cn
羅氏(Roche)旗下血癌藥 Lunsumio 獲捷報,成為首個美 FDA 核准的雙標靶抗體(CD20xCD3)藥物! https://geneonline.news/roche-lunsumio-fda-approved/?variant=zh-cn